10 Cheap Pharmaceutical Stocks to Buy According to Analysts

5. GSK plc (NYSE:GSK)

Price Target Upside: 29.94% 

GSK plc (NYSE:GSK), formerly known as GlaxoSmithKline, is a global pharmaceutical and healthcare corporation based in the United Kingdom that creates and distributes a variety of medications, vaccines, and consumer health items. With more than 20 vaccines in its portfolio, the firm is a leader in immunology, respiratory therapies, and vaccines. It creates cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs.

GSK plc (NYSE:GSK) reported impressive financial results for Q4 2024, demonstrating solid growth across key metrics. Sales increased by 8% to over £31 billion in 2024. Additionally, core operating profit rose by 13%, while core earnings per share (EPS) grew by 12%.

The company’s strong performance was primarily driven by its Specialty Medicines segment, which saw a 19% increase in sales. Notably, Oncology sales nearly doubled to more than £1.4 billion, while HIV sales grew by 13% for the full year.

GSK plc (NYSE:GSK)’s pipeline continues to strengthen, with 11 positive phase III trials reported in 2024. The company anticipates five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. This robust pipeline supports GSK’s long-term growth prospects, with the company raising its 2031 sales target to over £40 billion.